Pfizer Inc. (NYSE:PFE) Shares Sold by Bank Julius Baer & Co. Ltd Zurich

Bank Julius Baer & Co. Ltd Zurich cut its position in Pfizer Inc. (NYSE:PFE) by 0.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,055,639 shares of the biopharmaceutical company’s stock after selling 4,182 shares during the quarter. Bank Julius Baer & Co. Ltd Zurich’s holdings in Pfizer were worth $59,182,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Briaud Financial Planning Inc acquired a new stake in shares of Pfizer in the third quarter valued at $30,000. Mizuho Securities Co. Ltd. acquired a new position in Pfizer during the 3rd quarter worth $34,000. VisionPoint Advisory Group LLC grew its stake in Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares in the last quarter. GoalVest Advisory LLC grew its stake in Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 811 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners acquired a new position in Pfizer during the 4th quarter worth $36,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of Pfizer stock traded down $1.01 on Thursday, hitting $25.26. The stock had a trading volume of 47,041,425 shares, compared to its average volume of 41,958,969. Pfizer Inc. has a 52-week low of $25.23 and a 52-week high of $40.37. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The stock has a market cap of $143.04 billion, a price-to-earnings ratio of 70.17, a P/E/G ratio of 1.19 and a beta of 0.61. The company’s 50 day moving average price is $27.05 and its 200 day moving average price is $28.50.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.29. The business had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business’s quarterly revenue was down 41.3% on a year-over-year basis. During the same period in the previous year, the business earned $1.14 EPS. On average, research analysts anticipate that Pfizer Inc. will post 2.24 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 6.65%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio is presently 466.67%.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Guggenheim assumed coverage on Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 target price for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Monday, April 15th. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research note on Thursday, January 4th. Finally, Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Eleven equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $36.33.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.